Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure
about
Detection and analysis of resistance mutations of hepatitis B virusUltra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genomeAssociation of preexisting drug-resistance mutations and treatment failure in hepatitis B patientsCharacterization of treatment-naive HIV/HBV co-infected patients attending ART clinic of a tertiary healthcare centre in eastern IndiaDifferent Variants in Reverse Transcriptase Domain Determined by Ultra-deep Sequencing in Treatment-naïve and Treated Indonesian Patients Infected with Hepatitis B VirusIn vitro evaluation of novel antiviral activities of 60 medicinal plants extracts against hepatitis B virus.Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy.Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy.Profile of hepatitis B virus resistance mutations against nucleoside/nucleotide analogue treatment in Chinese patients with chronic hepatitis B.Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates.Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B.Clinical relevance of hepatitis B virus variantsIdentification of acetyltransferase genes (HAT1 and KAT8) regulating HBV replication by RNAi screening.Biological characteristics of the rtA181T/sW172* mutant strain of Hepatitis B virus in animal model.Antiviral efficacy of entecavir versus entecavir plus adefovir for hepatitis B virus rtA181V/T mutants aloneDrug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naïve chronic HBV patients.Therapeutic advances in the management of chronic hepatitis B infection.Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and Thailand.Detection of lamivudine-resistant variants and mutations related to reduced antigenicity of HBsAg in individuals from the cities of Santos and São Paulo, Brazil.Ultradeep pyrosequencing and molecular modeling identify key structural features of hepatitis B virus RNase H, a putative target for antiviral interventionNew universal primers for genotyping and resistance detection of low HBV DNA levels.Recent advances in the treatment of chronic hepatitis B.Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues.Management of antiviral drug resistance in chronic hepatitis BIncidence of natural resistance mutations in naïve chronic hepatitis B patients: a systematic review and meta-analysis.Posttransplantation prophylaxis with primary high-dose hepatitis B immunoglobulin monotherapy and complementary preemptive antiviral add-on.Pharmacotherapeutic options for hepatitis B.Molecular diagnosis of entecavir resistanceMolecular epidemiology and genetic diversity of hepatitis B virus in Ethiopia.Use of nucleoside analogs in patients with chronic hepatitis B in Nepal: A prospective cohort study in a single hospital.Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment.Amino acid polymorphism in the reverse transcriptase region of hepatitis B virus and the relationship with nucleos(t)ide analogues treatment for preventing mother-to-infant transmission.Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis.Hepatitis B virus reverse transcriptase mutations in treatment Naïve chronic hepatitis B patients.The diversity of chronic hepatitis B virus infections within blood donors in England and North Wales 2005 through 2010.Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B.Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir.
P2860
Q28266666-F6DDD0A7-4EC6-4712-9644-CC4EC1F6E8DFQ28484005-F6228E27-0873-4B1C-9FA4-A588E64D8C7BQ28535003-B20A610E-8647-45F2-A518-263098BA7A7FQ28536346-957428D8-724F-40E4-8145-A6713BF9169CQ33693776-EC963F90-E800-486A-B0FA-27F674E1AE62Q33846595-6828726B-5414-41AD-8655-317DD1F56EF6Q34080966-17C5FBCB-38A9-41CA-8E98-2B790E244B0CQ34175570-9885431F-3D2A-4988-9F98-F061AC0AD52CQ34508158-88BC14AA-DF21-4517-A06F-233B907F7D51Q34647599-84A589FC-C8DD-40EB-9501-DA40DE0D998CQ35221837-22FFFC0F-2194-4126-8D81-AA234A1B7E5FQ35668730-9FCA6DAC-D177-4895-9852-1C2A4100DE29Q36346801-84716CC0-E58A-4F90-B711-F379CF828E12Q36448260-0ABFDDD2-15F9-4DEB-92CF-510F3D813693Q36606780-50F99876-F108-496E-A276-A093E386C1D3Q36765571-3C8E7F1B-4DEF-4361-9836-F9BCBCBFB5D7Q36971785-8E23677A-D410-43BB-BC7E-F363AC977796Q37099761-60EF5189-BCED-4D19-A137-1A6098479593Q37278241-7BBDEF4D-87D6-4E66-AC30-9B1201B31A7AQ37356794-2D787AF4-3767-4C53-B097-40CFE667F7ECQ37502756-7197F300-5B00-4F69-BD68-D052B391A5B7Q37547736-35E4A3F2-69BC-4352-A0D2-B3D01BF88BB3Q37726789-C70A63F2-388A-4EEE-8F74-DBC03253AC29Q37891094-74FC125C-65AF-457F-BE34-FBDCE188778EQ38074646-5DA35F98-7845-40FB-B214-6DEC00B24CAAQ38247981-38EFB5F3-D63B-4128-A58C-6935E60D8FB4Q38260502-A49598C4-8C01-4D6F-8961-44894F7EF028Q38475751-33B11811-0A47-45C5-AAC9-06D3F645902FQ38631076-080A23BF-784C-4633-A181-BA0922D44E5DQ40789723-135D058C-78ED-4106-9D96-C163750652E6Q40885942-7B00BF97-48AE-4EA0-9608-F9D8374F8FBCQ41549327-3E479ACE-56AC-4CD2-8DBC-9196A8C334D6Q42131024-5EE4D47B-63B3-4D47-8360-FEE4D003D2BBQ42217478-A3A1CB7B-D33D-4A95-8D54-3F32169F65DEQ42245098-17CC25EF-A2DD-44FA-897C-E1E7349BA2FCQ42278809-20422DF3-A613-466F-AA0D-F7B69CFDD1CFQ43998760-0D00A0C3-087F-4F44-A306-E9C2A4DA20E7Q44087733-3DD0D737-733E-4928-A5B2-D4C6BCFF6F53Q44418225-D584CFB8-D8D3-428B-A588-F3472ACE933EQ44937235-41AA8456-B7DD-405C-96CD-BFC7934E7F79
P2860
Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Primary resistance, multidrug ...... nsequence of treatment failure
@en
type
label
Primary resistance, multidrug ...... nsequence of treatment failure
@en
prefLabel
Primary resistance, multidrug ...... nsequence of treatment failure
@en
P2860
P1476
Primary resistance, multidrug ...... nsequence of treatment failure
@en
P2093
Stephen Locarnini
P2860
P2888
P304
P356
10.1007/S12072-008-9048-3
P577
2008-03-28T00:00:00Z